Roche Holding AG said Thursday that John Reed, head of pharma research and early development, has decided to leave the company and will be replaced by William Pao.
Mr. Pao is currently global head of the oncology discovery and translational area at the research and development department and will assume his new role on April 2, Roche said. He will also become a member of the company’s enlarged corporate executive committee.
“Since joining Roche in 2014, William has been instrumental in the build-up of cancer immunotherapy and molecular targeted therapies,” said Chief Executive Severin Schwan, on the appointment.
By Alberto Declaux
With a first to market advantage, Ferring’s Rebyota has seen early positive adoption from gastroenterologists and infectious disease specialist in the first month post-launch. As part of their Launch Dynamix™: C.diff service, Spherix reports, while new monthly initiations are modest, a majority of physicians trialing Rebyota report high satisfaction.
Global biopharmaceutical firm UCB has entered an early drug discovery collaboration with Aitia. The collaboration is aimed at discovering and validating new drug targets and drug candidates that are linked to clinical endpoints causally in Huntington’s disease, a debilitating genetic disorder.
Foundry Innovation & Research 1—known by its much catchier acronym, FIRE1—announced Wednesday the close of a $25 million financing round. It was led by a pair of new investors in the company: Andera Partners and Novo Holdings, the holding and investment company that serves as the controlling shareholder for Novo Nordisk and Novozymes.